Filing Details
- Accession Number:
- 0001140361-18-027475
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-05 19:46:45
- Reporting Period:
- 2018-06-01
- Accepted Time:
- 2018-06-05 19:46:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1501989 | Cytomx Therapeutics Inc. | CTMX | Pharmaceutical Preparations (2834) | 273521219 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1706863 | Debanjan Ray | C/O Cytomx Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco CA 94080 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-05-31 | 1,187 | $17.90 | 5,928 | No | 5 | A | Direct | |
| Common Stock | Acquisiton | 2018-06-01 | 3,000 | $1.26 | 8,928 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-06-01 | 3,000 | $25.93 | 5,928 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-06-01 | 3,000 | $0.00 | 3,000 | $1.26 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,710 | 2023-12-10 | No | 4 | M | Direct |
Footnotes
- The shares were acquired under the issuer's Employee Stock Purchase Plan on May 31, 2018.
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades in prices ranging from $25.75 to $26.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
